NEW YORK (GenomeWeb) – Myriad Genetics announced today that it has signed an expanded companion diagnostics research partnership agreement with AbbVie. The drug developer will use Myriad's myChoice HRD companion diagnostic and a menu of tumor tests to identify non-small cell lung cancer patients who would be likely to respond to AbbVie's PARP inhibitor, veliparib, in combination with chemotherapy.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Direct-to-consumer genetic testing companies have offered to test families separated at the southern US border, but that raises ethical issues.

CNBC reports that confirming a positive result from 23andMe's BRCA health report can be expensive.

The New York Times reports on a project to develop a tree DNA database to uncover illegal logging.

In PLOS this week: links between gut microbiome and colorectal cancer mutations, targeted sequencing uncovers genetic susceptibilities to epilepsy in Koreans, and more.